<code id='89FD177370'></code><style id='89FD177370'></style>
    • <acronym id='89FD177370'></acronym>
      <center id='89FD177370'><center id='89FD177370'><tfoot id='89FD177370'></tfoot></center><abbr id='89FD177370'><dir id='89FD177370'><tfoot id='89FD177370'></tfoot><noframes id='89FD177370'>

    • <optgroup id='89FD177370'><strike id='89FD177370'><sup id='89FD177370'></sup></strike><code id='89FD177370'></code></optgroup>
        1. <b id='89FD177370'><label id='89FD177370'><select id='89FD177370'><dt id='89FD177370'><span id='89FD177370'></span></dt></select></label></b><u id='89FD177370'></u>
          <i id='89FD177370'><strike id='89FD177370'><tt id='89FD177370'><pre id='89FD177370'></pre></tt></strike></i>

          Home / fashion / explore

          explore


          explore

          author:comprehensive    Page View:27954
          Alexis Borisy
          Venture capitalist Alexis Borisy Vanessa Leroy for STAT

          EQRx is done, sold for its cash.

          The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.

          advertisement

          The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In